Industry Roundup: Nutrilite, No-GMO Similac, Supreme Court, Herbalife VPs
This article was originally published in The Tan Sheet
Executive Summary
Nutrilite ingredient granulation expands; GMO-free Similac debuts; Herbalife adds corporate VPs; Supreme Court likely not taking cosmetics preemption case; OTC device claim nixed in U.K.; and more news in brief.
You may also be interested in...
Supreme Court Asked To Consider Pre-emption In Drug Vs. Cosmetic Litigation
The Supreme Court asks the Solicitor General for an amicus in a case examining whether FDA regulation pre-empts state litigation on the cosmetics/drugs regulatory divide. The case could have implications for the personal care industry as states increasingly claim oversight by clarifying FDA’s division between drugs and cosmetics.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.